



| Revenue | Over $500 million See Exact Annual Revenue |
|---|---|
| Employees | Over 1,000Exact Company Size |
| Primary Industry | 5417 Scientific Research & Development Services |
| Additional NAICS Codes | 325412 Pharmaceutical Preparation Manufacturing |
| Address | 21823 30th Drive Se Bothell, WA 98021 |
| Seagen | Revenue Est. ($ Million) | Growth Rate (%) | # Employees |
|---|---|---|---|
| 2025 | Over $500 million Details in Premium Report | ||
| 2024 | |||
| 2023 | |||
| 2021 | |||
| 2020 | |||
| 2019 | |||
|
1-Year Growth Rate: 3-Year Growth Rate (CAGR): | ![]() |
| Seagen P&L | $ Millions |
|---|---|
| Revenue (Sales) | ![]() |
| Cost of Goods Sold | |
| Gross Profit | |
Operating Expenses | |
| Advertising | |
| Salaries and wages | |
| Other Operating Expenses | |
| Total Operating Expenses | |
| Operating Income | |
| EBITDA | |
| EBIT (Earnings Before Interest and Taxes) | |
| Net Profit | |
| Trademark | Date |
|---|---|
| LET'S TALK BLADDER CANCER Providing healthcare information | 03/23/2022 |
| TIVDAQ Pharmaceutical preparations for use in humans, namely, chemotherapeutics for the treatment of diseases and conditions; Pharmaceutical preparations for use in humans, namely, biopharmaceuticals for the treatment of diseases and conditions, namely, cancer; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology, ophthalmology, gastroenterological disorders, and tissue and organ transplantology | 04/27/2021 |
| TIVDAKT Pharmaceutical preparations for use in humans, namely, chemotherapeutics for the treatment of diseases and conditions; Pharmaceutical preparations for use in humans, namely, biopharmaceuticals for the treatment of diseases and conditions, namely, cancer; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and inflammatory disorders; pharmaceutical preparations for use in dermatology, oncology, hematology, ophthalmology, gastroenterological disorders, and tissue and organ transplantology | 04/27/2021 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| LEIDOS | Denver, CO | 100 |
| NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA | Albuquerque, NM | 30 |
| INC RESEARCH | Raleigh, NC | 27 |
| RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK | Albany, NY | 17 |
| FLUOR MARINE PROPULSION | West Mifflin, PA | 15 |
| SYNEOS HEALTH | Raleigh, NC | 13 |
| ILLUMINA | San Diego, CA | 12 |
| UT-BATTELLE | Oak Ridge, TN | 11 |
| PRA HOLDINGS | Raleigh, NC | 11 |
| Company | Headquarters | Revenue ($ MM) |
|---|---|---|
| EXPLORE VENTURES | Kent, WA | 100 |
| SEAGEN | Bothell, WA | 82 |
| STEMCELL TECHNOLOGIES | Kent, WA | 6 |
| INVENTPRISE | Redmond, WA | 4 |
| VIOME LIFE SCIENCES | Bellevue, WA | 3 |
| GLOBAL HEALTH LABS | Kirkland, WA | 3 |
| Company | Revenue ($ MM) |
|---|---|
![]() | |